Related Experiment Videos
25-hydroxycholecalciferol in the treatment of renal osteodystrophy in haemodialysed patients
Insights
This study found that 25-hydroxyvitamin D3 (25-OHD3) supplementation in dialysis patients did not improve renal osteodystrophy. Higher doses caused hypercalcemia, with minimal benefits on bone lesions and high parathyroid hormone levels.
Area of Science:
- Nephrology
- Endocrinology
- Bone Metabolism
Background:
- Renal osteodystrophy is a common complication in patients undergoing maintenance hemodialysis.
- Vitamin D deficiency is prevalent in these patients, impacting calcium and bone metabolism.
Purpose of the Study:
- To evaluate the efficacy of 25-hydroxyvitamin D3 (25-OHD3) in treating renal osteodystrophy in hemodialysis patients.
- To assess the effects of 25-OHD3 on biochemical parameters, calcium absorption, and bone histology.
Main Methods:
- A study involving 6 patients on maintenance hemodialysis.
- Administration of 25-OHD3 at doses of 50 and 100 microgram/day.
- Monitoring of biochemical data, intestinal calcium absorption, and bone biopsies.
Main Results:
- Low-dose 25-OHD3 (50 microgram/day) did not improve biochemical markers or calcium absorption.
- High-dose 25-OHD3 (100 microgram/day) led to hypercalcemia in all patients.
- Some patients showed a decrease in alkaline phosphatase, but hyperphosphatemia and elevated iPTH persisted.
- Bone biopsies revealed minimal improvement in bone lesions after 8 months of treatment.
- Combination therapy with 1,25-(OH)2D3 showed faster improvement in biochemical parameters and iPTH.
Conclusions:
- 25-OHD3 supplementation at doses that normalize calcium levels offers limited benefit for the osteitis fibrosa component of renal osteodystrophy.
- Higher doses risk hypercalcemia and do not adequately control secondary hyperparathyroidism.
- Active vitamin D metabolites like 1,25-(OH)2D3 may be more effective in managing renal osteodystrophy.
Abstract:
The effects of 25-OHD3 on renal osteodystrophy have been studied in 6 patients on maintenance haemodialysis. Administration of 25-OHD3, 50 microgram/day, did not improve biochemical data and intestinal absorption of calcium. With a dose of 100 microgram/day in all patients an increase in blood calcium levels eventually reaching hypercalcemic values was observed. In two cases a fall in alkaline phosphatase toward normal values was noted. In the same cases the treatment-induced hyperphosphatemia, uncontrolled by AI(OH)3 supplementation and similarly high iPTH levels were observed. In two cases repeated bone biopsy following 8 months treatment and not show substantial improvement of bone lesions. In one case addition of 1,25-(OH)2D3 to the treatment with 25-OHD3 led to a more rapid improvement in biochemical parameters and iPTH serum levels. Doses of 25-OHD3 capable to correct blood calcium levels and intestinal absorption of calcium, may have minimal benefit on the osteitis fibrosa component of the bone lesion.